Globus Medical Reports Second Quarter 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/1/2026
- Wall Street ends choppy session lower as tech shares drop
- Meta Platforms stock surges 8% on cloud business plans
- Humanoid robot component stocks surge on supply-chain optimism
- Oil prices fall 1% to 4-month lows as progress in US-Iran talks cools supply concerns
- Trump discloses over $1.4 billion in crypto income in 2025 filing
- Whirlpool to close Mexico plant, expects $165M restructuring cost
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Cantor Fitzgerald Starts Forward Industries (FWDI) at Overweight
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- DISH DBS files prepackaged chapter 11 to repay debt, wind down wireless
Globus Medical (GMED) PT Raised to $65 at Needham & Company
August 2, 2018 8:15 AM EDTNeedham & Company raised its price target on Globus Medical (NYSE: GMED) to $65.00 (from $58.00) while maintaining a Buy rating following 2Q earnings report. Revenue was $173M vs. consensus of $168M and non-GAAP EPS was $0.44 vs. consensus of $0.35.
For 2018, GMED raised its revenue... More
